LZM012 not checked
Livzon Pharmaceutical Group Inc.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Recombinant anti-human IL-17A/F humanized monoclonal antibody injection”In the company’s words, NCT06110676 on ClinicalTrials.gov
- Tested for
- Psoriasis (2 trials)
- Main trialPhase 3
- “This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients”In the company’s words, NCT06110676 on ClinicalTrials.gov
Other drugs for Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Unknown | Apr 2025 | A Study to Evaluate the Efficacy and Safety of LZM012 | |
| Phase 3Completed | 26 Jan 2026 | A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026